01228

1.5804.53%
MA

Mark Alan Goldberg

Member of Strategic Advisory Board

Dr. Mark Alan Goldberg, M.D. serves as Member of Advisory Board at Sharp Therapeutics Corp. since January 2026. He serves as Member of Cancer Business Advisory Board at Anixa Biosciences, Inc. since October 2023. He serves as Member of Strategic Advisory Board at Canbridge Limited. He serves as Independent Non-Executive Director of Avacta Group Plc since August 17, 2021. He serves as Director of Walden Biosciences, Inc. He had been an Acting Chief Medical Officer of CANbridge Life Sciences Ltd. since October 20, 2015, until 2018. Dr. Goldberg has been Member of Strategic Advisory Board at CANbridge Pharmaceuticals Inc. Dr. Goldberg served in various executive capacities of increasing responsibility at Synageva BioPharma Corp. or Synageva, a biopharmaceutical company, from 2011 to 2014. Dr. Goldberg served as Executive Vice President of Global Medical and Regulatory Strategy at Synageva BioPharma Corp. from January 2014 to October 2014. Dr. Goldberg has served as an Executive Officer of the Synageva BioPharma. Dr. Goldberg served as Senior Vice President of Product Development, Medical & Regulatory Affairs at Synageva BioPharma Corp. since September 2011 to January 2014, Senior Vice President of Global Medical and Regulatory Affairs from September 2011 to 2015 and served as its Senior Vice President of Product Development. Dr. Goldberg joined the Synageva BioPharma from Genzyme Corporation, where Dr. Goldberg served as Senior Vice President of Clinical Development and Global Therapeutic Group Head of Oncology and Personalized Genetic Health from 2009 to July 2011. He served in various management capacities of increasing responsibility at Genzyme Corporation from 1996-2011. While at Genzyme, he was Chairman of the Early Product Development Board. He played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme, Aldurazyme, Myozyme and Lumizyme. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute, where he still holds appointments. He served as a Director of Audentes Therapeutics, Inc. from December 13, 2017, to January 15, 2020. He has been a Member of Strategic Advisory Board at CANbridge Life Sciences Ltd since September 26, 2013. He had been an Independent Director of GlycoMimetics, Inc. since July 8, 2014 until February 21, 2025. He had been an Independent Director of ImmunoGen, Inc. since November 2011, until February 12, 2024. He served as an Independent Director at Idera Pharmaceuticals, Inc. since March 2014 until 2022. He was an Independent Director of Blueprint Medicines Corporation since June 2015 until July 18, 2025. He served as a Director of aTyr Pharma, Inc. since April 2015 until December 11, 2017. He served as a Director of Synageva BioPharma Corp. (alternatively Private Synageva) from October 2008 to December 15, 2011. From 2010 to 2017, Dr. Goldberg served on the Board of Directors of the New England Division of the American Cancer Society and ACS Cancer Action Network (CAN) volunteer. Since December 2017, he has been on the eastern New England Board of the American Cancer Society serving as the Chair from December 2017 until April 2020 and since January 2019 has been a member of the national Board of Directors of the American Cancer Society. He has been a Clinical Associate Professor of Medicine at Harvard Medical School since 1996. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Dr. Goldberg plays a central role in developing medical and regulatory strategy and ensuring the successful progress and advancement of pipeline programs. He has extensive experience in oncology, rare disease and gene therapy development and the biotechnology industry. Dr. Goldberg holds A.B. (magna cum laude) in biochemistry and molecular biology from Harvard College and M.D. (cum laude) from Harvard Medical School.

Positions